Activity Overview

This educational activity is an archive of the live conference held from January 23 to 25, 2026.

Target Audience

This educational activity is intended for oncologists involved in the treatment and management of patients with lung cancer. Nurse practitioners, nurses, physician assistants, pharmacists, clinical investigators, fellows, and other health care professionals interested in the treatment of lung cancer may also participate.

Learning Objectives

Evaluate efficacy and safety data from recent clinical trials on established and emerging therapeutic approaches for lung cancer.

Module 5: Localized Advanced Oligometastatic NSCLC

GET STARTED WITH THIS PROGRAM:

Create Account Already Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.25 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc; Daiichi Sankyo, Inc; Exact Sciences Corp; Merck Sharp & Dohme LLC; Partner Therapeutics, Inc; and Revolution Medicines.

Module 5: Localized Advanced Oligometastatic NSCLC

GET STARTED WITH THIS PROGRAM:

Related Content